Tsubota Laboratory Incorporated (4890) AI Stock Analysis

• Market Cap: ¥8.82B
• Dividend Yield: N/A
• Average Volume (3M): 29.20K
• Price to Earnings (P/E): 48.3
• Beta (1Y): 0.59
• Revenue Growth: 101.17%
• EPS Growth: N/A
• Country: JP
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -7.79
• Shares Outstanding: 25,794,300
• 10 Day Avg. Volume: 35,800
• 30 Day Avg. Volume: 29,196
• PEG Ratio: -0.37
• Price to Book (P/B): 6.35
• Price to Sales (P/S): 7.43
• P/FCF Ratio: -30.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥372.00
• Price Target Upside: 10.39% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 62 Neutral
• Price Target: ¥372.00 ▲(10.39% Upside)

The overall stock score is primarily influenced by strong financial performance, with robust revenue growth and a solid balance sheet. However, technical indicators show bearish trends, and the high P/E ratio suggests overvaluation, which negatively impacts the score.

Tsubota Laboratory Incorporated Business Overview & Revenue Model

Company Description

Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan.

How the Company Makes Money

Tsubota Laboratory generates revenue through the sale of its precision measurement instruments and analytical solutions, which are used in medical diagnostics and environmental testing. The company has established key revenue streams from direct sales to hospitals, laboratories, and research institutions, as well as through partnerships with distributors that expand its market reach. Additionally, Tsubota Laboratory may engage in service contracts for maintenance and calibration of its instruments, providing ongoing revenue. Significant partnerships with healthcare providers and research organizations further enhance its earnings by facilitating the adoption of its technologies in critical applications.

Tsubota Laboratory Incorporated Financial Statement Overview

Summary

Tsubota Laboratory Incorporated shows strong revenue growth and operational efficiency, reflected in improved profit margins. The balance sheet is solid, with low leverage and a strong equity base. However, cash flow challenges need to be addressed to ensure long-term sustainability and growth potential.

Income Statement

The company demonstrated strong revenue growth, with a significant increase from 2024 to 2025. Gross profit margins are high, indicating efficient production and cost management. However, the net profit margin has been volatile, with a significant loss in 2024 followed by a recovery in 2025. The EBIT and EBITDA margins have improved, reflecting better operational efficiency.

Balance Sheet

The balance sheet is robust, with a strong equity position and a low debt-to-equity ratio, indicating financial stability. The company has a high equity ratio, suggesting a solid capital structure. However, the decrease in cash and short-term investments over the years warrants attention.

Cash Flow

The cash flow statement shows challenges, with negative operating cash flow in recent years, indicating potential liquidity issues. Free cash flow has been negative, which could impact future investments and growth. However, the company had positive free cash flow in earlier years, suggesting potential for recovery.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.36B	1.36B	673.53M	954.69M	640.92M	687.50M
Gross Profit	1.16B	1.18B	21.38M	719.14M	557.02M	606.76M
EBITDA	253.28M	310.89M	-602.60M	184.19M	241.07M	271.61M
Net Income	177.43M	205.77M	-641.32M	90.18M	153.32M	201.61M
Balance Sheet
Total Assets	2.02B	2.50B	2.30B	2.67B	1.62B	1.08B
Cash, Cash Equivalents and Short-Term Investments	1.47B	1.54B	1.88B	2.16B	1.17B	610.77M
Total Debt	85.26M	90.38M	116.90M	139.34M	223.82M	242.35M
Total Liabilities	627.88M	915.85M	927.93M	722.59M	873.44M	487.55M
Stockholders Equity	1.39B	1.59B	1.37B	1.95B	744.35M	591.03M
Cash Flow
Free Cash Flow	0.00	-331.75M	-313.35M	-20.27M	582.69M	-8.63M
Operating Cash Flow	0.00	-317.75M	-301.35M	28.49M	654.91M	36.72M
Investing Cash Flow	0.00	-14.55M	-12.00M	-54.03M	-72.23M	-43.60M
Financing Cash Flow	0.00	-12.25M	35.74M	1.01B	-18.53M	236.97M

Tsubota Laboratory Incorporated Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 337.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4890, the sentiment is Negative. The current price of 337 is below the 20-day moving average (MA) of 352.70, below the 50-day MA of 361.28, and below the 200-day MA of 388.94, indicating a bearish trend. The MACD of -6.01 indicates Positive momentum. The RSI at 39.94 is Neutral, neither overbought nor oversold. The STOCH value of 8.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4890.

Tsubota Laboratory Incorporated Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3417	75 Outperform	¥19.24B	6.72	8.52%	1.84%	3.70%	37.00%
3544	67 Neutral	¥11.07B	15.20	7.83%	1.25%	4.08%	51.63%
4350	63 Neutral	¥14.09B	11.67	7.77%	2.57%	5.93%	-36.11%
4890	62 Neutral	¥8.82B	48.30	―	―	101.17%	―
8095	60 Neutral	¥20.53B	-10.71	-10.03%	3.48%	12.75%	-191.21%
2796	58 Neutral	¥6.10B	-23.21	-5.34%	2.70%	15.66%	56.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Tsubota Laboratory Incorporated Corporate Events

Tsubota Laboratory Reports Strong Financial Recovery in FY2025

Tsubota Laboratory, Inc. reported significant financial improvement for the fiscal year ended March 31, 2025, with net sales doubling and a return to profitability. This positive shift in financial performance underscores the company’s strengthened position in the industry, although the forecast for the next fiscal year indicates a slight decline in profits, suggesting potential challenges ahead.